NDLI: Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia

Content Provider	PubMed Central
Author	Hill, Brian T. Matt, Kalaycio
Copyright Year	2015
Abstract	Chronic lymphocytic leukemia (CLL) is a hematologic malignancy derived from a clonal population of mature B-lymphocytes characterized by relatively low CD20 antigen expression. Although the disease often takes an indolent course, the majority of patients will eventually require therapy. Standard treatment for medically fit patients includes purine analogs and/or alkylating agents in addition to the type I anti-CD20 monoclonal antibody, rituximab. This therapy is inherently myelosuppressive and can result in significant morbidity and even mortality in patients with impaired performance status due to age and/or medical comorbidities. Historically, treatment options for the elderly or frail patient population were limited to mono-therapy with the oral alkylating agent, chlorambucil, rituximab, or another type I anti-CD20 monoclonal antibody ofatumumab. Recently, a newer-generation anti-CD20 monoclonal antibody, obinutuzumab, was developed for patients with CLL. Obinutuzumab is a humanized type II monoclonal antibody that appears to have more direct antibody-dependent cell-mediated cytotoxicity (ADCC) and possibly more direct cytotoxicity in vitro than previously available type I antibodies. A large Phase III prospective randomized clinical trial for older patients with impaired renal function and/or significant medical comorbidities demonstrated that when compared to conventionally-dosed rituximab and chlorambucil, the combination of chlorambucil and obinutuzumab administered at a dose and schedule involving early loading doses improved response rates and progression-free survival without significantly increasing toxicity. Results of this pivotal trial led to the FDA (US Food and Drug Administration) approval of obinutuzumab in combination with chlorambucil for frontline treatment of CLL. Obinutuzumab expands the armamentarium of active and less-toxic targeted agents in the evolving treatment landscape of CLL, providing physicians and patients with an additional therapeutic option.
Related Links	http://dx.doi.org/10.2147/ott.s68770
Ending Page	2397
Starting Page	2391
File Format	PDF
ISSN	11786930
e-ISSN	11786930
Journal	OncoTargets and therapy
Volume Number	8
Language	English
Publisher	Dove Medical Press
Publisher Date	2015-08-01
Access Restriction	Open
Rights Holder	Dove Medical Press
Subject Keyword	Pharmacology (medical) Oncology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical) Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia

Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective

Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab.

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia

Similar Documents

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia

Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective

Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab.

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia